Cargando…
Sodium selenate as a therapeutic for tauopathies: A hypothesis paper
In a large proportion of individuals with fronto-temporal lobar degeneration (FTLD), the underlying pathology is associated with the misfolding and aggregation of the microtubule associated protein tau (FTLD-tau). With disease progression, widespread protein accumulation throughout cortical and subc...
Autores principales: | Dilcher, Roxane, Malpas, Charles B., Walterfang, Mark, Velakoulis, Dennis, O’Brien, Terence J., Vivash, Lucy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389397/ https://www.ncbi.nlm.nih.gov/pubmed/35992608 http://dx.doi.org/10.3389/fnagi.2022.915460 |
Ejemplares similares
-
Sodium selenate as a disease-modifying treatment for mild–moderate Alzheimer’s disease: an open-label extension study
por: Vivash, Lucy, et al.
Publicado: (2021) -
A phase 1b open‐label study of sodium selenate as a disease‐modifying treatment for possible behavioral variant frontotemporal dementia
por: Vivash, Lucy, et al.
Publicado: (2022) -
A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia
por: Vivash, Lucy, et al.
Publicado: (2020) -
Phase II randomised placebo-controlled trial of sodium selenate as a disease-modifying treatment in chronic drug-resistant temporal lobe epilepsy: the SeLECT study protocol
por: Vivash, Lucy, et al.
Publicado: (2023) -
Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial
por: Vivash, Lucy, et al.
Publicado: (2021)